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Inappropriate Sinus Tachycardia
Brian Olshansky, MD,* Renee M. Sullivan, MD†
Iowa City, Iowa; and Columbia, Missouri
Inappropriate sinus tachycardia (IST) is a syndrome in which the sinus heart rate is inexplicably faster than ex-
pected and associated symptoms are present. The heart rate at rest, even in a supine position, can exceed 100
beats/min; minimal activity accelerates the rate rapidly and substantially. Patients with IST may require restric-
tion from physical activity. Mechanisms responsible for IST are understood incompletely. It is important to distin-
guish IST from so-called appropriate sinus tachycardia and from postural orthostatic tachycardia syndrome, with
which overlap may occur. Because the long-term outcome seems to be benign, treatment may be unnecessary
or may be as simple as physical training. However, for patients with intolerable symptoms, therapeutic mea-
sures are warranted. Even at high doses, -adrenergic blockers, the first-line therapy, often are ineffective; the
same is true for most other medical therapies. In rare instances, catheter- or surgically- based right atrial or sinus
node modification may be helpful, but even this is fraught with limited efficacy and potential complications. Overtreat-
ment, in an attempt to reduce symptoms, can be difficult to avoid, but is discouraged. (J Am Coll Cardiol 2013;61:
793–801) © 2013 by the American College of Cardiology Foundation
ublished by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.0740
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rInappropriate sinus tachycardia (IST), a syndrome charac-
terized by unexpectedly fast sinus rates at rest, with minimal
physical activity, or both, is manifest by a spectrum of
symptoms including palpitations, weakness, fatigue, dizzi-
ness, or near syncope. Acceleration in rate with minimal
exercise is excessive and heart rate recovery is prolonged.
Sinus tachycardia, even if excessively fast, generally is a
transient and reversible condition with an explainable cause
and a rate appropriate for the circumstance (caffeine inges-
tion, anxiety, deconditioning, and so on.) (1). IST is a more
long-standing problem that is not as easy to explain. Herein,
we review IST, explore its mechanisms, and review man-
agement strategies.
What Is a Normal Sinus Rate?
Healthy, normal individuals, at rest, have sinus rates of 50 to
90 beats/min, generally lower than the intrinsic sinus rate
(i.e., devoid of autonomic influence), in part because of
vagal tone (2–4). In 432 otherwise normal medical staff and
prisoners, the intrinsic resting sinus rate was age dependent
(3). Individuals 15 years of age had an average intrinsic heart
rate of more than 118 beats/min; 15% of those 15 to 30
years of age had intrinsic rates of more than 115 beats/min.
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younger individuals. For those older than 45 years, 15% had
an intrinsic sinus rate of more than 100 beats/min. Rates
were reproducible, not dependent on time of day, and only
slightly dependent on exercise.
In CORDIS (Israeli Cardiovascular Occupational Risk
Factors Determination in Israel Study), the percent difference
in mean heart rate (supine to standing) in 5,428 subjects (mean
age: 40.4  11.5 years, 74% blue collar, 58% physically active)
was greater among women than men (12.7% vs. 11.6%, p 
.03). Heart rate was associated independently with height
p  0.0001), cigarette smoking (p  0.0001), and coffee
drinking (p  0.001) and was associated inversely with age
p  0.002), blood pressure elevation (p  0.0005), and
hysical activity (p  0.0001) (5).
nappropriate Sinus Tachycardia:
he Clinical Presentation
o specific heart rate best defines IST, yet patients with
ST generally have resting daytime sinus rates of more than
00 beats/min and average 24-h heart rates of more than 90
eats/min that are not explained by physiologic demands or
onditions known commonly to increase heart rate. Patients
ith IST often have multiple, incapacitating symptoms
ncluding palpitations, dyspnea, dizziness, lightheadedness,
nd near syncope, but the symptoms may not be dependent
n heart rate. Associated emotional and psychiatric prob-
ems often are identified, but any relationship to IST is
ncertain. Treatment of tachycardia alone may not amelio-
ate debilitating symptoms, the predominant problem in
his condition. IST may be difficult to distinguish from a
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postural orthostatic tachycardia
syndrome (POTS).
Epidemiology of
Inappropriate
Sinus Tachycardia
Most patients are young and fe-
male, but the epidemiologic charac-
teristics are uncertain. Episodes tend to become noticed
abruptly and persist over months or years, but the natural
history is obscure and the onset may be surreptitious. The
prognosis generally is benign. Perhaps one reason for a
benign prognosis is that although IST patients have faster
heart rates, the rate slows somewhat during sleep and in
various diurnal patterns (6). Long-term consequences are
few, yet reported series are small, follow-up is limited, and
populations are diverse. IST rarely is associated with
tachycardia-induced cardiomyopathy (7), although isolated
reports do exist (8,9).
Still et al. (10) identified 7 of 604 middle-aged subjects
from OPERA (Oulu Project Elucidating Risk of Athero-
sclerosis) as meeting criteria for IST (resting daytime sinus
rate 100 beats/min or average 24-h rate  90 beats/min).
ersonality measurements (except hostility scores) were
ormal. Over 6.0  2.4 years, these and 9 IST patients
iagnosed previously had a benign course, although they
ad palpitations and fast average heart rates (90  2
eats/min vs. 89 8 beats/min) over the long term. IST has
een identified in older individuals, as well (11). In this
roup, no significant differences in echocardiographic
arameters were noted between baseline and follow-up
xaminations.
egulation of the Sinus Rate
s a multicomponent hierarchical structure, the sinus node
s complex and tightly controlled (12) by more than 16
egionally varying, autonomically influenced currents. The
ole of calcium cycling (13) versus If (14) remains contro-
versial (15). The If current is commonly regarded as the
redominant current responsible for sinus rate, but this is
learly a simplification (13). No specific channelopathy is
mplicated in IST, although some have been suspected (16).
Parasympathetic regulation of resting sinus rate depends
n M2 muscarinic receptor-mediated activation of IKAch via
G protein-coupled, inwardly rectifying potassium channels
(Fig. 1) (17). M2 receptors activate L-type calcium channels
ICa-L), negatively influencing adenylate cyclase and having
a stimulatory effect on G1 proteins to suppress If.
Calcium clocks and cellular membrane voltage, driven by
-adrenergic sympathetic nervous system activation or ex-
trinsic catecholamines, can be blocked, in part, by If block-
de. Although several drugs and ions can block the If
Abbreviations
and Acronyms
HRV  heart rate variability
IST  inappropriate sinus
tachycardia
POTS  postural
orthostatic tachycardia
syndromecurrent, their effects are nonspecific. Other If blockers havebeen developed, but only ivabradine is available commer-
cially. Subsidiary pacemakers, residing in the superior por-
tion of the sinus node, are activated by sympathetic stimu-
lation such that a depolarizing shift in the If activation
curve, a potentiation of ICa-L, a potentiation of IK, a
hyperpolarized shift in IK activation curve, an acceleration of
he deactivation of IK, and a potentiation of IST occur (14).
Although phasic vagal (parasympathetic) activation su-
persedes sympathetic activation (called accentuated antago-
nism) (18), tonic sympathetic activation overshadows inter-
mittent vagal activation. Catecholamine excess or sympathetic
activation, with or without vagal inhibition, could cause IST.
Mechanisms Responsible for
Inappropriate Sinus Tachycardia
Explanatory mechanisms for IST (Table 1), likely multifac-
torial and complex, amount to a form of dysautonomia (19),
an intrinsic sinus node problem, or both. A viable, consis-
tent, unified mechanism has yet to be identified.
Animal Models
Catecholamine injections into the sinus node fat pad con-
taining autonomic ganglia (20) or high-frequency stimula-
tion of the anterior right ganglionated plexi (21) accelerate
the sinus rate, but so do many things. Thus, we find these
data unconvincing as a mechanism for IST in patients (1).
Hyposensitivity of muscarinic receptors (22); central and
peripheral nociceptive effects (23,24); depressed efferent
vagal activation (25); neurohormonal modulation (26); non-
muscarinic, nonadrenergic, vagally mediated mechanisms
(27); or hypothalamic paraventricular nucleus stimulation
(28) likewise can cause sinus tachycardia.
Vasointestinal peptide, twice as potent as norepinephrine
(29) and more potent than epinephrine (30), can increase sinus
rate. Central gamma-aminobutyric acid (GABA)-nergic (31)
and serotonin 1-A receptor activation (32) in the medullary
raphe and parapyramidal regions affecting autonomic outflow
can initiate sinus tachycardia. Histamine (33), neuropeptides
(29) (including neuropeptide Y), phenyl-histidine-isoleucine,
substance P (34), -opioid receptor activation (35), or other
mediators (36) may be involved. M2 receptor abnormalities,
sinus node channelopathies, or circulating mediators could
cause IST, but none have been identified. Indeed, much
remains to be learned about inappropriate and, for that matter,
appropriate sinus tachycardia.
Clinical Studies
Clinical reports include small, select populations of patients
with IST. Autoantibodies to ganglionic acetylcholine recep-
tors, described in POTS (37), have been postulated to be
responsible for, but have not been identified in, IST. Chiale
et al. (38) suspected anti--receptor immunoglobulin G
antibodies as a cause for IST. Studying 21 IST patients
versus 15 controls, -anti-adrenergic receptor antibodies
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fractions showing anti--receptor antibodies caused long-
asting increases in cyclic AMP. In 5 IST patients (and 5
ontrols), immunoglobulin G fractions were evaluated using
OS-7 cells transfected with genes encoding for the -1
nd -2 adrenergic receptors. No anti-M2 cholinergic
eceptor antibodies were identified.
Heart rate variability (HRV) in IST patients is inconsis-
ent. In one report, all temporal and power spectral HRV
arameters were reduced, suggesting reduced parasympa-
hetic tone, after correcting for heart rate (39). However,
Figure 1 Heart Rate Control via the Autonomic Nervous System
Predominant (not all-inclusive) regulators of the sinus rate are depicted. Sinus nod
IKr, and the L-type calcium (Ca2) channel, among others, regulated in part via G
receptor (RyR) Ca2 release from the sarcoplasmic reticulum (SR), has an import
larly at rest) involves parasympathetic activation via acetylcholine (Ach) and nitric
affects the muscarinic (M2) receptor via Ach and works by affecting intracellular cy
receptors via norepinephrine to increase cAMP. Both limbs of the autonomic nervo
system and peripheral nerve terminals. There are multiple checks and balances th
they are extraordinarily complex. Presently, it is not clear what part(s) of the syste
delayed rectifier K current; If  funny current; INaCa  sodium/calcium exchangeome data support sinus rate elevation in IST independent 0f an autonomic mechanism (40). In another report, the
ow-frequency HRV spectrum was higher in IST patients
consistent with higher sympathetic tone) versus controls,
ut no consistent pattern was observed, and results may be
ependent on population and age (11).
Morillo et al. (41) evaluated 6 women with IST (age
ange 23 to 38 years) and 10 controls. HRV low to high
requency ratio in supine and head-up tilt positions was
imilar in both groups. The cardiovagal response measured
y the cold-face test was seen less frequently in IST than in
ontrols (6% of IST patients vs. 24% of controls, p 
vation is under the control of various cellular currents, including IKAch, If, INaCa,
modulation (G). Additionally, the so-called calcium clock, involving ryanodine
e in sinus rate determination. Further regulation and modulation of rate (particu-
NO), in part via nitric oxide synthase (NOS). Parasympathetic nerve activation
MP (cGMP) and cyclic AMP (cAMP) in part. Sympathetic activation stimulates -1
tem are regulated and interact at multiple levels, including the central nervous
out the entire regulatory system and, despite the simplifications shown here,
e predominant driver of increased rates in inappropriate sinus tachycardia. IKr 
t; NE  norepinephrine;   stimulates;   inhibits.e acti
protein
ant rol
oxide (
clic G
us sys
rough
m is th
curren.001). Patients with IST were hypersensitive to isoproter-
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Inappropriate Sinus Tachycardia February 26, 2013:793–801enol. However, intrinsic heart rates were higher in IST
patients. In these patients, -blockers often were effective
41); this is not our general experience.
Leon et al. (42) investigated whether baroreflex gain
iffered in 8 IST patients versus 9 controls. Individuals with
ST had a higher mean heart rate (78.8  5.3 beats/min vs.
8.5  4.2 beats/min) and blood pressure, but heart rates
or IST patients were not in the range many consider IST.
aroreflex gain during orthostatic stress was reduced signif-
cantly in IST patients, and the change in baroreceptor gain
uring head-up tilt stabilization was blunted markedly in
hose considered to have IST. The intrinsic heart rate (3)
bserved in 7 of 8 patients was faster than predicted
115.7  2.7 observed beats/min vs. 110.6  1.4 expected
eats/min, p  0.01). Only 25% considered to have IST
howed a hypersensitive response to catecholamines, point-
ng to the sinus node as the problem, rather than the
utonomic nervous system.
Still et al. (16) studied the response to adenosine after
-adrenergic and cholinergic blockade in 18 IST patients
(mean age 46  15 years) versus controls (114  17
beats/min vs. 79  11 beats/min). Adenosine did not stop
or slow the sinus rate. After adenosine, reflex increase in the
sinus rate was greater in controls than in IST patients
(21.2  9.7% vs. 8.5  8.8%, p  0.001), supporting the
enet that an accelerated intrinsic sinus rate may be the primary
bnormality. They postulated that IST may be the result of
eficient function of the acetylcholine-sensitive and
denosine-sensitive potassium channel. In clinical studies,
-adrenergic receptor supersensitivity (43), M2 receptor
blockade (44,45), or the role of neuropeptide neurotrans-
mitters (46) have been considered. Variations in diurnal
patterns have been speculated to help to characterize forms
Potential Mechanisms ofInappropriat Sinu TachycardiaTable 1 Potential Mechan sms ofInappropriate Sinus Tachycardia
Intrinsic sinus node overactivity: channelopathy
Autonomic influence
Decreased parasympathetic activity
Hyposensitivity of muscarinic receptors
Decreased efferent vagal activation
Increased sympathetic activity
-receptor autoantibodies
Combined
Baroreceptor activity
Neurohormonal modulation
Vasoactive intestinal polypeptide
Histamine
Norepinephrine
Epinephrine
Serotonin 1-A receptor activation
Central GABA-nergic activation
Substance P
GABA gamma-aminobutyric acid.of IST (6).Ultimately, the causal mechanism for the abnormally fast
sinus rate is unknown. The initial event may be a trigger,
such as a viral infection or toxin exposure (47), but evidence
is scant. In our experience, excess hydrocarbon exposure
may be one mechanism; halogenated hydrocarbons can
sensitize the myocardium to catecholamines and can in-
crease the sinus rate (48,49). The problem, however, may lie
in the sinus node itself. Lipofuscin-laden vacuoles have been
identified as an ultrastructural marker noted in 3 patients
with IST for whom the sinus node was excised (50).
Causes for Sinus Tachycardia
Critical to the diagnosis of IST is the need to exclude
specific physiological and psychological triggers for appro-
priate sinus tachycardia, including exercise, anxiety, panic
attacks, and pain. Anticholinergics, catecholamines, alcohol,
caffeine, cocaine, tobacco, -blocker withdrawal, and su-
raventricular tachycardia ablation causing vagal denerva-
ion increase sinus rate (51–54). Several medical conditions
an explain sinus tachycardia as well (Table 2). Central
echanisms may be responsible for sinus tachycardia caused
y insults to the brain, including head trauma, especially to
he brainstem.
Most IST patients are otherwise completely healthy.
ecause IST seems to be more common in health care
roviders (55), consideration of access to stimulants and
ther drugs (e.g., insulin) must be considered in the evalu-
tion of appropriate versus inappropriate sinus tachycardia.
ccult substance abuse and psychiatric causes such as panic
ttacks must be considered in the differential diagnosis. In
ne report, 100% of patients with IST had some psychiatric
iagnosis (schizophrenia, depression, panic disorder, or
omatoform disorder) (56).
iagnosing Inappropriate Sinus Tachycardia
he diagnosis of IST is based on persistent or recurrent
inus tachycardia on 12-lead electrogram or by long-term
Explainable Causes ofSinus T chycardia to Consider BeforeD agnosing In ppropriate Sinus Tachycardia
Table 2
Ex l inable Causes of
Sinus Tachycardia to Consider Before
Diagnosing Inappropriate Sinus Tachycardia
Drugs, Substances,
Medications, Interventions Medical Conditions
Anticholinergics Anemia
Catecholamines Dehydration
Alcohol Exercise
Caffeine Anxiety
Tobacco Pain
Cocaine Pulmonary embolus
-blocker withdrawal Fever
Supraventricular tachycardia ablation Pericarditis
Aortic or mitral regurgitation
Myocardial infarction
Pneumothorax
HyperthyroidismHypoglycemia
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February 26, 2013:793–801 Inappropriate Sinus Tachycardiamonitoring that is not otherwise explainable. Invasive test-
ing, such as electrophysiology studies, is not useful for
making the diagnosis, although it may be useful to exclude
a concomitant supraventricular tachycardia mechanism (57).
The evaluation of sinus tachycardia must take into account
whether the rhythm is paroxysmal or persistent. Careful
analysis of a 12-lead electrocardiogram should consider
P-wave morphological features. If the P-wave is the same or
similar to that in normal sinus rhythm, IST is possible. If
paroxysmal, atrial tachycardia, including sinus node re-
entry, should be excluded. If tachycardia occurs gradually
with postural change, a tilt-table test may indicate POTS;
with tilting, the increase in heart rate is nearly immediate in
IST (58). If tachycardia is persistent and an underlying
cause can be determined, IST is not present. In the patient
with generally persistent episodes for which no cause can be
determined, however, IST may be diagnosed. IST is a
diagnosis of exclusion.
Commonly, there is confusion between IST and POTS;
overlap between the 2 exists (Table 3) (59). Tachycardia in
IST is not postural as it is in POTS. In POTS, there is a
persistent increase in heart rate by more than 30 beats/min
or a rate of more than 120 beats/min within 10 minutes of
changing from a supine to an upright position in the
absence of orthostatic hypotension. As with IST, patients
with POTS often have multisystem symptoms. There is
venous (including splanchnic) pooling, -hypersensitivity
nd -hypersensitivity, baroreceptor dysfunction, hypovole-
ia, the presence of brainstem dysregulation, or a combi-
ation thereof. One has to wonder: is tachycardia in POTS
nappropriate? Probably so.
reatment of Inappropriate Sinus Tachycardia
anaging IST (controlling symptoms and reducing rate)
emains a substantial challenge, especially because the syn-
rome itself is nebulous. Heart rate control, however, does
ot necessarily eliminate symptoms. Controlling the sinus
ate in asymptomatic patients with IST is controversial
ecause the treatment may be worse than the syndrome
tself. In IST, no one therapy reduces heart rate and
ymptoms completely and effectively, likely related to the
omplexity of the problem and the lack of full understand-
ng of the causes.
Many treatment recommendations have been made for
atients with IST, but these therapies have not been well
Inappropriate Sinus Tachycardia Versus Postural Orthostatic TachyTable 3 Inappropriate Sinus Tachycardia Versus Postural Ortho
Inappropriate Sinus Tachycardia
Definition Abnormally fast sinus rhythm at rest or minimal activity that acce
beyond expectations and is out of proportion to physiologic ne
not resulting from an explainable underlying cause
Heart rate Resting daytime heart rate exceeds 100 beats/min and average
rate on 24-h Holter monitor exceeds 90 beats/minDiagnosis Diagnosis of exclusionested. -adrenergic blockers, even at high doses, generally
are ineffective and tend to be associated with other symp-
toms. Other treatments (fludrocortisone, volume expansion,
pressure stockings, phenobarbital, clonidine, psychiatric
evaluation, erythropoietin) have been suggested, but may be
harmful and have not been proven (59).
A study of 19 patients with POTS supported the use of
exercise training to improve quality of life and to maintain
upright cardiac output compared with the use of propranolol
(60). We suspect that exercise training also may help IST
patients. Benzodiazepines may be helpful, but this drug
class has not been evaluated carefully. It is likely that many
IST patients have a superimposed anxiety disorder. Al-
though not reported, benzodiazepine and -blocker com-
inations, in the hands of an empathetic physician, may be
ffective for many IST patients (Coghlan CH, personal
ommunication). Indeed, effective patient communication
nd attention seem to improve outcomes (56).
adiofrequency Catheter Ablation
adiofrequency ablation in attempts to modify the sinus
ode or eliminate sympathetic inputs, at best, is partially
ffective, but has been tested only in small populations.
arly reports suggested that ablation had value; we remain
entative and do not recommend aggressive attempts to
blate the sinus node in patients with IST on a routine basis.
In 16 drug-refractory, highly symptomatic patients with
ST, total sinus node ablation (n  4) or sinus node
modification (n  12) was performed via radiofrequency
nergy delivery to sites of earliest atrial activation. For those
ho had sinus node modification, a chronotropic response
as still present with a reduction in maximal heart rate
132.8  6.5 beats/min vs. 179.5  3.6 beats/min, p 
.001). Holter monitoring showed a decrease in maximal
nd mean heart rate (167.2  2.6 beats/min vs. 96.7  5.0
eats/min, p  0.001, and 125.6  5.0 beats/min vs. 54.1 
.3 beats/min, p  0.001, respectively) with long-term
enefits. Two patients required pacing, one had transient
ight diaphragmatic paralysis and another had transient
uperior vena cava syndrome (61).
In a report of 29 IST patients, ablation reduced sinus
ates to less than 90 beats/min acutely in 22 patients (62).
or 13 acutely successful ablations, radiofrequency ablation
t the site of earliest endocardial activation resulted in
igration of earliest activation from the high lateral right
a Syndromec Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome
s Condition of orthostatic intolerance leading to abnormal increase in
heart rate with change in position
Persistent increase in heart rate by more than 30 beats/min or absolute
pulse of more than 120 beats/min within 10 min of moving from a
supine to upright position in the absence of orthostatic hypotensioncardistati
lerate
cessity
heartTilt table
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Inappropriate Sinus Tachycardia February 26, 2013:793–801atrium with a progressive reduction in rate. For the other 9
patients with a successful acute outcome, reduction in rate
occurred abruptly. Symptoms recurred 4.4 3 months after
he procedure in 6 of 22 patients, but after additional
rocedures in 3 patients, symptoms were eliminated suc-
essfully (62).
In a more recent report, long-term results of 3-dimensional
ap-guided ablation of IST were reported in 39 patients
35 women, mean age 31  9 years) (56). The shift in the
arliest sinus node activation site after -adrenergic block-
de was compared with the shift after ablation. After
blation, the mean sinus rate normalized (72 8 beats/min)
ith a more pronounced shift in caudal activation along the
rista terminalis than with esmolol, but 21% of patients
xperienced recurrent IST and underwent repeat ablation.
he authors concluded that adrenergic hypersensitivity is
ot the only mechanism responsible for IST and that
-dimensional guidance helped facilitate ablation (56). In
ome cases, with a thick terminal crest, an epicardial
blation approach has been used (63). Ablation of the
rcuate ridge in a combined epicardial and endocardial
pproach has been described (63,64).
Although we agree that detailed 3-dimensional mapping
elps to identify sinus nodal sites to ablate in patients with
ST, including the use of noncontact mapping (65,66), we
ave observed migrating tachycardia rates with progressive
blation at superior sites in the sinus node in patients with
ST. We are not convinced that a single 3-dimensional
apping approach, even one that uses unipolar mapping, in
n attempt to derive the origin of the sinus node activation,
s any better than bipolar mapping (66,67).
Such ablation can be fruitless because tachycardia ulti-
ately may come from other sinus nodal sites or from the
trioventricular junction after complete sinus node obliter-
tion. This has been observed in surgical ablations and even
fter sinus node removal (68). Furthermore, symptoms can
ersist despite sinus node slowing, and the benefits may be
nly short term (69).
It becomes extraordinarily important to distinguish the
otential mechanisms responsible for sinus tachycardia,
ecause for patients with POTS, radiofrequency ablation of
he sinus node will have devastating effects, exacerbating
ymptoms or making hemodynamics worse. If POTS was
he original problem, incorrectly diagnosed as IST, blunting
he acceleration in heart rate during position change by
inus node ablation could prevent the needed sinus response
o overcome inappropriate vasodilation or lack of appropri-
te vasoconstriction. Severe postural hypotension therefore
ay ensue.
Narrowing of the superior vena cava (70), damage to the
hrenic nerve (71), and bradycardia requiring a pacemaker
an occur. The latter complication may develop days after
blation. Because complications are probably underreported,
hese devastating outcomes for an otherwise young healthy
erson who may continue to have symptoms and tachycar-
ia should raise serious concerns about proceeding withnterventional approaches. Patients and referring physicians
ust be cognizant that although symptoms may be substan-
ial and patients may be highly motivated, consequences of
ggressive therapeutic attempts may seriously outweigh any
otential benefit.
urgical Ablation
urgical ablation of the sinus node may be ineffective
ecause in patients with IST, escape rhythms, including
hose from the atrioventricular junction, also may be inap-
ropriately fast. Over a 17-year period, 9 medically refrac-
ory patients (mean age 33 6 years) with symptoms lasting
3.4  10.9 years underwent median sternotomy (cardio-
ulmonary bypass time 73  25 min) for surgical isolation
f the sinus node, cryoablation, or both; 2 patients under-
ent radiofrequency ablation via a right inframammary
ncision. Over a mean of 6.4  5.9 years, 4 underwent
epeat postoperative ablation attempts; 1 required a pace-
aker (72). Other methods have been used to ablate the sinus
ode surgically, either using a thoracoscopic approach (68,73),
n off-pump beating-heart sinus isolation and ablation through
minithoracotomy (72), or direct complete removal of the
inus node (74). Partial cardiac denervation and sinus node
blation have been attempted (75).
Complete surgical sympathectomy has not been well
ested yet. However, innervation may remain via the intrin-
ic cardiac nervous system (76). Even complete sympathec-
omy may not address the primary problem, and therefore
ay treat IST ineffectively. Further, IST has been observed
fter heart transplantation even after complete central au-
onomic denervation (77). Surgical ablation is not recom-
ended, except for patients who are completely debilitated
ymptomatically and for whom everything else has failed.
he aggressiveness of the surgical therapies testifies to the
act that patients with IST can be highly motivated to
ursue substantial and risky procedures to eliminate their
ymptoms.
merging Therapy for
nappropriate Sinus Tachycardia
mall studies (78–80) and several case reports have dem-
nstrated the potential value of the If blocker ivabradine to
reat IST; the drug is not available in the United States.
vabradine can have a dramatic effect on heart rate and can
low it from a mean of 100 beats/min to fewer than 75
eats/min. The maximum heart rate can slow from a mean
f 160 beats/min to 120 beats/min. The minimum heart
ate also can slow over time.
Ivabradine was evaluated in 10 female patients (median
ge 32.5 years, range: 12 to 57 years) with IST (78).
vabradine (5 to 7.5 mg twice daily) with a -blocker (n 
) or as monotherapy (n  7) reduced maximum and mean
eart rates (baseline: maximal heart rate 176  45 beats/
in, mean heart rate: 84  11 beats/min; ivabradine:maximal heart rate: 137  36 beats/min, mean heart rate:
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ate did not change, but symptoms were ameliorated or
uppressed in all 8 contacted after a mean of 16  9
months (78).
In another report (79), the efficacy and safety of ivabra-
dine were tested in 18 consecutive symptomatic patients
(mean age: 45  15 years); 16 completed the study. There
was a significant reduction of median and maximal heart
rates over 6 months, with small changes in the minimal
heart rate. There was improvement in exercise tolerance.
Phosphene toxicity limited use of the drug in small numbers
of patients, but otherwise, it was well tolerated.
Ivabradine may precipitate excess bradycardia (especially
in combination with -blockers or calcium-channel block-
rs) and may cause headaches or other side effects. It should
ot be used with strong CYP 3A4 inhibitors or in patients
ith liver or severe renal dysfunction. It should be avoided
n patients who are hypotensive, pregnant, or breastfeeding.
hese latter are of most concern for the IST patient.
General Approach
ur general approach to patients in whom sinus tachycardia
s present and IST is presumed includes the following:
. Determine if, and when, sinus tachycardia is present and
if the problem is reproducible and persistent. Consider if
any explainable cause of tachycardia exists and determine
if symptoms are postural, because this may be the result
of POTS, or exacerbated by physical activity. Consider
psychiatric issues, exclude substance abuse, and carefully
counsel the patient on the risks and benefits of any
interventional therapy. Consider that there is no neces-
sity to move to aggressive ablation interventions if
simpler approaches do not work. Ensure the patient is
aware that the therapeutic options, including ablation,
have limited value and may cause tremendous harm.
. If IST is diagnosed, determine if there is a trigger or an
event that precipitated the symptoms because this may
help to determine the longevity of the problem. For
some, a postviral syndrome can be associated with POTS
and this may be short lived. If the patient is otherwise
young and healthy, the problem may last 5 years or more
before dissipating.
. Patients with IST often have symptoms independent of
heart rate. It is critical to determine if the heart rate is
associated directly with the symptoms, because in this
setting, treatment of the heart rate likely will make a
difference. Consider a multidisciplinary approach to rule
out psychiatric issues that may be exacerbating the
symptoms and may be alleviated by other approaches.
. Treatment begins with modest doses of -blockers. No
specific -blocker is more effective than another. Exer-
cise training is recommended. Potential stimulants in the
diet (such as caffeine or alcohol) should be eliminated.
. Ivabradine at a dose of 5.0 to 7.5 mg twice daily, if available,
may be highly effective and should be considered.. Consider radiofrequency ablation only if sinus rates are
extremely fast, the patient clearly has IST with symp-
toms resulting from sinus tachycardia, and all other
therapies have failed.
onclusions
inus tachycardia generally is explainable. When it is not, it
ay be the result of IST, a difficult to characterize, symptomatic
ondition that represents a spectrum of disorders related to
ncreased sinus node automaticity, disordered autonomic
ctivation, or both. There may be an overlap between
onditions caused by orthostatic intolerance (e.g., POTS) or
nxiety. Evaluation of patients with this condition begins
ith assessment and exclusion of all possible explainable
auses for sinus tachycardia. In some cases, this may require
ong-term follow-up to determine presence of substance
buse or psychiatric abnormalities.
For the remaining patients, it is critical to distinguish
OTS from IST because inappropriate treatment of sus-
ected IST with sinus node ablation (when it is actually
isdiagnosed POTS) will have a devastating effect. Treat-
ent can be as simple as avoiding triggers of tachycardia
nd exercise training. Because tachycardia-induced cardio-
yopathy develops rarely, the primary reason to treat IST is
o improve symptoms. Caution is advised to limit aggressive
reatment attempts in patients with IST because the cure
ften can be worse than the condition itself.
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